← Back to guidelines
Gastroenterology58 papers

Gastric intestinal metaplasia

Last edited: 4/16/2026

Overview

Gastric intestinal metaplasia (GIM) is a premalignant condition characterized by the transformation of normal gastric mucosa into intestinal-type epithelium, increasing the risk of progression to gastric cancer 1.

Diagnosis

  • Endoscopic Identification: Typically identified incidentally during upper endoscopy 1.
  • Biopsy Confirmation: Histological examination of biopsy samples is essential for diagnosis 1.
  • Grading Systems: Utilizes the Vienna classification system to grade severity (Intestinal Metaplasia types 1-3) 1.
  • Management

  • Shared Decision-Making: Surveillance recommendations based on patient-specific risk factors, including age, family history, and extent of metaplasia 1.
  • Surveillance Frequency: Variable based on individual risk stratification; guidelines emphasize individualized approach 1.
  • Special Populations

  • No Specific Guidance Provided: Abstracts do not provide detailed management strategies for pregnancy, pediatrics, elderly, or specific comorbidities 1.
  • Key Recommendations

  • Implement Shared Decision-Making: Engage in shared decision-making with patients regarding GIM surveillance, considering individual risk factors 1 (Evidence: Moderate).
  • Increase Patient Communication: Communicate GIM findings and surveillance options more frequently to patients post-2020 guidelines 1 (Evidence: Moderate).
  • Tailored Surveillance Plans: Develop surveillance plans tailored to patient-specific risk factors rather than adopting a one-size-fits-all approach 1 (Evidence: Expert opinion).
  • References

    1 Rouphael C, Elkin B, El Dahdah J, Moufawad M, Yang Q, Bena J et al.. Practice Trends among US Gastroenterologists following the 2020 American Gastroenterological Association Guidelines on Gastric Intestinal Metaplasia: Data from a Tertiary Care Center. Journal of clinical gastroenterology 2025. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG